Business Wire

  1. QIAGEN To Advance AI-Driven Drug Discovery With Graph-Based AI And Curated Bioinformatics Knowledge With NVIDIA 5/19/2026

    QIAGEN announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.

  2. LenioBio And Twist Bioscience Enter Into A Collaboration To Further Enable AI Drug-Discovery 5/8/2026

    LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation.

  3. Altasciences And Certara Announce Strategic Partnership To Accelerate Early Drug Development 5/7/2026

    Altasciences, a fully integrated drug development solution company, and Certara, a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.

  4. Waiv Enters Collaboration With Daiichi Sankyo To Deliver AI-Derived Biomarkers For ADC Program 5/6/2026

    Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program.

  5. Simulations Plus And NVIDIA Collaborate To Scale GPU-Accelerated, AI-Assisted Modeling Workflows 5/6/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

  6. Alloy Therapeutics And Institute For Protein Innovation Announce Strategic Collaboration To Advance Next-Generation Antibody Discovery 5/5/2026

    Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery.

  7. U.S. FDA Grants Priority Review Of New Drug Application For Gilead's Once-Daily HIV Treatment Of Bictegravir Plus Lenacapavir 4/29/2026

    Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed.

  8. Immunome Announces Submission Of New Drug Application To U.S. FDA For Varegacestat For The Treatment Of Adults With Desmoid Tumors 4/29/2026

    Immunome, Inc., a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.

  9. U.S. Food And Drug Administration Accepts New Drug Application For Zipalertinib For The Treatment Of Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations 4/28/2026

    Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab.

  10. Celerion Announces Majority Investment From THL Partners 4/22/2026

    Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies.